Notably, some mutations in specific genes and pathways, such as microsatellite instability [91], APC, TP53, KRAS, BRAF, WNT signaling, and TGF-β/SMAD2/3 signaling [92,93,94,95,96,97], have emerged as prognostic biomarkers for CRC. This evidence concerns the gene SMAD2 and colorectal carcinoma.